Breakthrough trial tests Life-Saving TB treatment for most vulnerable HIV patients

NCT ID NCT04738812

First seen Jan 07, 2026 · Last updated Apr 21, 2026 · Updated 12 times

Summary

This large study tested whether a stronger, intensified tuberculosis (TB) treatment regimen could save more lives than standard treatment in HIV patients hospitalized with TB who have very low immune cell counts. Over 1,300 participants received either the intensified treatment (with higher drug doses plus additional medications) or standard WHO-recommended treatment for 8 weeks, followed by identical continuation treatment. Researchers tracked deaths and safety over 48 weeks to see which approach worked better for this high-risk group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ignace Deen Hospital

    Conakry, Guinea

  • Jamot Hospital

    Yaoundé, Cameroon

  • MACHAVA Hospital

    Maputo, Mozambique

  • Mbarara Regional Referral hospital

    Mbarara, Uganda

  • National Center for HIV/AIDS, Dermatology and STD (NCHADS)

    Phnom Penh, Cambodia

  • University Teaching Hospital

    Lusaka, Zambia

Conditions

Explore the condition pages connected to this study.